vs

Side-by-side financial comparison of Abbott Laboratories (ABT) and Envista Holdings Corp (NVST). Click either name above to swap in a different company.

Abbott Laboratories is the larger business by last-quarter revenue ($11.5B vs $750.6M, roughly 15.3× Envista Holdings Corp). Abbott Laboratories runs the higher net margin — 15.5% vs 4.4%, a 11.1% gap on every dollar of revenue. On growth, Envista Holdings Corp posted the faster year-over-year revenue change (15.0% vs 4.4%). Abbott Laboratories produced more free cash flow last quarter ($2.6B vs $91.7M). Over the past eight quarters, Envista Holdings Corp's revenue compounded faster (9.7% CAGR vs 7.2%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Envista Forensics is a United States based company that provides forensic engineering and recovery solutions for the insurance, legal, and risk management industries in the United States and internationally. Originally LWG Consulting, Inc., The company rebranded itself as Envista Forensics in 2017.

ABT vs NVST — Head-to-Head

Bigger by revenue
ABT
ABT
15.3× larger
ABT
$11.5B
$750.6M
NVST
Growing faster (revenue YoY)
NVST
NVST
+10.5% gap
NVST
15.0%
4.4%
ABT
Higher net margin
ABT
ABT
11.1% more per $
ABT
15.5%
4.4%
NVST
More free cash flow
ABT
ABT
$2.5B more FCF
ABT
$2.6B
$91.7M
NVST
Faster 2-yr revenue CAGR
NVST
NVST
Annualised
NVST
9.7%
7.2%
ABT

Income Statement — Q4 2025 vs Q4 2025

Metric
ABT
ABT
NVST
NVST
Revenue
$11.5B
$750.6M
Net Profit
$1.8B
$32.9M
Gross Margin
57.0%
54.7%
Operating Margin
19.6%
9.8%
Net Margin
15.5%
4.4%
Revenue YoY
4.4%
15.0%
Net Profit YoY
-80.8%
2641.7%
EPS (diluted)
$1.01
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABT
ABT
NVST
NVST
Q4 25
$11.5B
$750.6M
Q3 25
$11.4B
$669.9M
Q2 25
$11.1B
$682.1M
Q1 25
$10.4B
$616.9M
Q4 24
$11.0B
$652.9M
Q3 24
$10.6B
$601.0M
Q2 24
$10.4B
$633.1M
Q1 24
$10.0B
$623.6M
Net Profit
ABT
ABT
NVST
NVST
Q4 25
$1.8B
$32.9M
Q3 25
$1.6B
$-30.3M
Q2 25
$1.8B
$26.4M
Q1 25
$1.3B
$18.0M
Q4 24
$9.2B
$1.2M
Q3 24
$1.6B
$8.2M
Q2 24
$1.3B
$-1.2B
Q1 24
$1.2B
$23.6M
Gross Margin
ABT
ABT
NVST
NVST
Q4 25
57.0%
54.7%
Q3 25
55.4%
55.3%
Q2 25
56.4%
54.2%
Q1 25
56.9%
54.5%
Q4 24
55.0%
57.1%
Q3 24
55.8%
52.8%
Q2 24
55.6%
51.6%
Q1 24
55.2%
57.1%
Operating Margin
ABT
ABT
NVST
NVST
Q4 25
19.6%
9.8%
Q3 25
18.1%
8.6%
Q2 25
18.4%
6.8%
Q1 25
16.3%
6.3%
Q4 24
17.4%
7.1%
Q3 24
17.5%
3.5%
Q2 24
16.1%
-182.2%
Q1 24
13.9%
7.7%
Net Margin
ABT
ABT
NVST
NVST
Q4 25
15.5%
4.4%
Q3 25
14.5%
-4.5%
Q2 25
16.0%
3.9%
Q1 25
12.8%
2.9%
Q4 24
84.1%
0.2%
Q3 24
15.5%
1.4%
Q2 24
12.5%
-181.9%
Q1 24
12.3%
3.8%
EPS (diluted)
ABT
ABT
NVST
NVST
Q4 25
$1.01
$0.20
Q3 25
$0.94
$-0.18
Q2 25
$1.01
$0.16
Q1 25
$0.76
$0.10
Q4 24
$5.26
$0.00
Q3 24
$0.94
$0.05
Q2 24
$0.74
$-6.69
Q1 24
$0.70
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABT
ABT
NVST
NVST
Cash + ST InvestmentsLiquidity on hand
$8.9B
$1.2B
Total DebtLower is stronger
$12.9B
$1.4B
Stockholders' EquityBook value
$52.1B
$3.1B
Total Assets
$86.7B
$5.7B
Debt / EquityLower = less leverage
0.25×
0.47×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABT
ABT
NVST
NVST
Q4 25
$8.9B
$1.2B
Q3 25
$7.7B
$1.1B
Q2 25
$7.3B
$1.1B
Q1 25
$6.8B
$1.1B
Q4 24
$8.0B
$1.1B
Q3 24
$7.8B
$991.3M
Q2 24
$7.2B
$1.0B
Q1 24
$6.7B
$948.5M
Total Debt
ABT
ABT
NVST
NVST
Q4 25
$12.9B
$1.4B
Q3 25
$1.4B
Q2 25
$1.4B
Q1 25
$1.4B
Q4 24
$14.1B
$1.4B
Q3 24
$1.4B
Q2 24
$1.5B
Q1 24
$1.5B
Stockholders' Equity
ABT
ABT
NVST
NVST
Q4 25
$52.1B
$3.1B
Q3 25
$51.0B
$3.1B
Q2 25
$50.6B
$3.1B
Q1 25
$48.8B
$3.0B
Q4 24
$47.7B
$2.9B
Q3 24
$39.8B
$3.1B
Q2 24
$39.3B
$3.0B
Q1 24
$38.8B
$4.1B
Total Assets
ABT
ABT
NVST
NVST
Q4 25
$86.7B
$5.7B
Q3 25
$84.2B
$5.6B
Q2 25
$84.0B
$5.7B
Q1 25
$81.4B
$5.5B
Q4 24
$81.4B
$5.4B
Q3 24
$74.4B
$5.5B
Q2 24
$73.0B
$5.4B
Q1 24
$72.5B
$6.6B
Debt / Equity
ABT
ABT
NVST
NVST
Q4 25
0.25×
0.47×
Q3 25
0.47×
Q2 25
0.46×
Q1 25
0.47×
Q4 24
0.30×
0.48×
Q3 24
0.46×
Q2 24
0.51×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABT
ABT
NVST
NVST
Operating Cash FlowLast quarter
$3.3B
$108.0M
Free Cash FlowOCF − Capex
$2.6B
$91.7M
FCF MarginFCF / Revenue
22.9%
12.2%
Capex IntensityCapex / Revenue
6.0%
2.2%
Cash ConversionOCF / Net Profit
1.87×
3.28×
TTM Free Cash FlowTrailing 4 quarters
$7.4B
$230.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABT
ABT
NVST
NVST
Q4 25
$3.3B
$108.0M
Q3 25
$2.8B
$78.7M
Q2 25
$2.0B
$88.7M
Q1 25
$1.4B
$300.0K
Q4 24
$2.9B
$132.4M
Q3 24
$2.7B
$70.7M
Q2 24
$2.0B
$93.1M
Q1 24
$1.0B
$40.3M
Free Cash Flow
ABT
ABT
NVST
NVST
Q4 25
$2.6B
$91.7M
Q3 25
$2.3B
$67.9M
Q2 25
$1.5B
$76.4M
Q1 25
$933.0M
$-5.6M
Q4 24
$2.1B
$123.8M
Q3 24
$2.1B
$63.3M
Q2 24
$1.4B
$86.3M
Q1 24
$627.0M
$29.3M
FCF Margin
ABT
ABT
NVST
NVST
Q4 25
22.9%
12.2%
Q3 25
20.2%
10.1%
Q2 25
13.9%
11.2%
Q1 25
9.0%
-0.9%
Q4 24
19.6%
19.0%
Q3 24
20.2%
10.5%
Q2 24
13.8%
13.6%
Q1 24
6.3%
4.7%
Capex Intensity
ABT
ABT
NVST
NVST
Q4 25
6.0%
2.2%
Q3 25
4.4%
1.6%
Q2 25
4.5%
1.8%
Q1 25
4.7%
1.0%
Q4 24
6.6%
1.3%
Q3 24
5.2%
1.2%
Q2 24
5.1%
1.1%
Q1 24
4.0%
1.8%
Cash Conversion
ABT
ABT
NVST
NVST
Q4 25
1.87×
3.28×
Q3 25
1.70×
Q2 25
1.15×
3.36×
Q1 25
1.07×
0.02×
Q4 24
0.31×
110.33×
Q3 24
1.64×
8.62×
Q2 24
1.51×
Q1 24
0.84×
1.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABT
ABT

Segment breakdown not available.

NVST
NVST

Other$375.8M50%
Specialty Productsand Technologies$188.4M25%
Equipmentand Consumables$186.4M25%

Related Comparisons